WHITE PAPER: The Future of Diagnostics for Immuno-oncology

Executive Summary:

The explosion of immuno-oncology (I/O) therapies has created a complicated, dynamic, and competitive landscape that is focused on patient selection for drug efficacy and differentiation.
Understanding both immune content and immune context is critical for differentiating patient response to enable a patient selection strategy.
A novel Computational Tissue Analysis (cTA™) platform can deliver data-rich tissue context information to support I/O drug development and provide clarity to diagnostic decisions, despite the complexity of tissue biomarkers.
The use of standard immunohistochemistry (IHC) assays and standard slide scanning to support cTA-based diagnostics simplifies the approach and provides for a clear regulatory pathway.

READY TO TAKE THE NEXT STEP?

Our Services

Pharma

Cell-based image analysis, assays, and partnership to advance clinical trials and regulatory acceptance.

Clinical Diagnostics

Dependable clinical diagnostic testing to connect patients to individualized, immuno-oncology therapies.

Flagship carefully tracks our tissue to ensure we can analyze every assay and stay on schedule.

We are trying to bridge from the discovery stage to clinical development. Flagship's pathologists and scientists provide critical input and the company helps us organize and analyze an incredible amount of data. I highly recommend Flagship for its expertise and support for drug development projects.

During clinical trials, I interact with our manufacturing, legal, pre-clinical, and biomarker teams. Our Flagship project manager understands our tight timeline and ensures delivery of the data we need, when we need it.

We are pleased to partner with Flagship Biosciences to integrate their machine learning/AI tools to provide cancer marker detection.

Flagship’s image analysis experts are flexible and willing to work with us to develop projects that meet the changing needs of our clinical trials drug development.

Flagship has a high reputation as a supplier of advanced IHC services and their CAP-CLIA environment is a perfect complement to our own testing facilities.

The ease of leveraging Flagship’s powerful solution is yet another massive differentiator of the company. Clients need not have to change their existing workflows, investments in technology, or even the assays that they use.

POSTERS & PUBLICATIONS